company background image
5302

Suven Life SciencesBSE:530239 Stock Report

Market Cap

₹25.4b

7D

-4.8%

1Y

108.0%

Updated

27 Oct, 2021

Data

Company Financials
530239 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

530239 Overview

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally.

Suven Life Sciences Competitors

Divi's Laboratories

NSEI:DIVISLAB

₹1.4t

Syngene International

BSE:539268

₹217.6b

Dishman Carbogen Amcis

BSE:540701

₹34.0b

Jubilant FoodWorks

NSEI:JUBLFOOD

₹500.0b

Price History & Performance

Summary of all time highs, changes and price drops for Suven Life Sciences
Historical stock prices
Current Share Price₹99.65
52 Week High₹42.05
52 Week Low₹124.40
Beta1.96
1 Month Change3.05%
3 Month Change18.28%
1 Year Change108.04%
3 Year Change-58.87%
5 Year Change-47.15%
Change since IPO278.90%

Recent News & Updates

Shareholder Returns

530239IN Life SciencesIN Market
7D-4.8%-4.2%-2.3%
1Y108.0%46.8%62.5%

Return vs Industry: 530239 exceeded the Indian Life Sciences industry which returned 46.8% over the past year.

Return vs Market: 530239 exceeded the Indian Market which returned 62.5% over the past year.

Price Volatility

Is 530239's price volatile compared to industry and market?
530239 volatility
530239 Beta1.96
Industry Beta0.36
Market Beta1

Stable Share Price: 530239 is more volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: 530239's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.

About the Company

FoundedEmployeesCEOWebsite
1989130Venkat Jastihttps://www.suven.com

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. It engages in drug discovery and development of new chemical entities (NCE) in central nervous system therapies. The company’s product candidates include SUVN-502 for the treatment of Alzheimer’s disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders.

Suven Life Sciences Fundamentals Summary

How do Suven Life Sciences's earnings and revenue compare to its market cap?
530239 fundamental statistics
Market Cap₹25.37b
Earnings (TTM)-₹1.14b
Revenue (TTM)₹68.55m

370.0x

P/S Ratio

-22.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
530239 income statement (TTM)
Revenue₹68.55m
Cost of Revenue₹1.03m
Gross Profit₹67.52m
Expenses₹1.20b
Earnings-₹1.14b

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-4.46
Gross Margin98.50%
Net Profit Margin-1,655.85%
Debt/Equity Ratio1.8%

How did 530239 perform over the long term?

See historical performance and comparison

Valuation

Is Suven Life Sciences undervalued compared to its fair value and its price relative to the market?

50.91x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 530239's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 530239's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 530239 is unprofitable, so we can't compare its PE Ratio to the Indian Life Sciences industry average.

PE vs Market: 530239 is unprofitable, so we can't compare its PE Ratio to the Indian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 530239's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 530239 is overvalued based on its PB Ratio (50.9x) compared to the IN Life Sciences industry average (3.6x).


Future Growth

How is Suven Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Suven Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Suven Life Sciences performed over the past 5 years?

-67.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 530239 is currently unprofitable.

Growing Profit Margin: 530239 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 530239 is unprofitable, and losses have increased over the past 5 years at a rate of 67.9% per year.

Accelerating Growth: Unable to compare 530239's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 530239 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (34.7%).


Return on Equity

High ROE: 530239 has a negative Return on Equity (-227.83%), as it is currently unprofitable.


Financial Health

How is Suven Life Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: 530239's short term assets (₹358.3M) exceed its short term liabilities (₹91.3M).

Long Term Liabilities: 530239's short term assets (₹358.3M) exceed its long term liabilities (₹37.1M).


Debt to Equity History and Analysis

Debt Level: 530239's debt to equity ratio (1.8%) is considered satisfactory.

Reducing Debt: 530239's debt to equity ratio has reduced from 12.1% to 1.8% over the past 5 years.

Debt Coverage: 530239's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if 530239's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is Suven Life Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 530239's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 530239's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 530239's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 530239's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 530239 is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 530239's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.4yrs

Average management tenure


CEO

Venkat Jasti (72 yo)

17yrs

Tenure

Mr. Venkateswarlu Jasti, also known as Venkat, M.Pharm. M.S. serves as Chairman of the Board and Managing Director at Suven Pharmaceuticals Limited since November 06, 2019. He serves as Managing Director a...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Venkat's total compensation is reasonable compared to companies of similar size in the Indian market.

Compensation vs Earnings: Venkat's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: 530239's management team is seasoned and experienced (6.4 years average tenure).


Board Members

Experienced Board: 530239's board of directors are considered experienced (7.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 100%.


Top Shareholders

Company Information

Suven Life Sciences Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Suven Life Sciences Limited
  • Ticker: 530239
  • Exchange: BSE
  • Founded: 1989
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹25.367b
  • Shares outstanding: 254.56m
  • Website: https://www.suven.com

Number of Employees


Location

  • Suven Life Sciences Limited
  • # 8-2-334, SDE Serene Chambers
  • 6th Floor
  • Hyderabad
  • 500034
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/27 15:39
End of Day Share Price2021/10/27 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.